keyword
MENU ▼
Read by QxMD icon Read
search

Fingolimod

keyword
https://www.readbyqxmd.com/read/29694732/pharmacokinetic-interaction-between-fingolimod-and-carbamazepine-in-healthy-subjects
#1
Olivier J David, Rhett Behrje, Parasar Pal, Hisanori Hara, Christian D Lates, Robert Schmouder
This open-label, single-sequence study in healthy subjects investigated the effects of steady-state carbamazepine on the pharmacokinetic (PK) profile of a single 2-mg dose of fingolimod. In period 1, a single oral dose of fingolimod 2 mg (day 1) was followed by PK and safety assessments up to 36 days. In period 2, carbamazepine was administered in flexible, up-titrated doses (600 mg twice daily maximum) for 49 days. Fingolimod was administered on day 35, followed by a study completion evaluation (day 71)...
April 25, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29689473/severe-aseptic-temporal-lobe-encephalitis-on-fingolimod
#2
Dalia L Rotstein, Aditya Bharatha, Daniel Selchen
We report the case of an MS patient with aseptic temporal lobe encephalitis while on treatment with fingolimod. This 49-year-old woman developed headache and decreasing level of consciousness after 3.5 years of fingolimod therapy. Imaging, CSF studies, and rapid clinical response to acyclovir suggested a viral etiology, although CSF cultures and viral PCR were negative. This case illustrates the potential for severe manifestations of infectious illnesses on fingolimod, which may have a predilection for the CNS and also include herpes virus infections, cryptococcus, and PML...
April 16, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29687345/modulatory-effects-of-fingolimod-fty720-on-the-expression-of-sphingolipid-metabolism-related-genes-in-an-animal-model-of-alzheimer-s-disease
#3
Henryk Jęśko, Przemysław L Wencel, Walter J Lukiw, Robert P Strosznajder
Sphingolipid signaling disturbances correlate with Alzheimer's disease (AD) progression. We examined the influence of FTY720/fingolimod, a sphingosine analog and sphingosine-1-phosphate (S1P) receptor modulator, on the expression of sphingolipid metabolism and signaling genes in a mouse transgenic AD model. Our results demonstrated that AβPP (V717I) transgene led with age to reduced mRNA expression of S1P receptors (S1PRs), sphingosine kinase SPHK2, ceramide kinase CERK, and the anti-apoptotic Bcl2 in the cerebral cortex and hippocampus, suggesting a pro-apoptotic shift in 12-month old mice...
April 23, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29686116/practice-guideline-recommendations-summary-disease-modifying-therapies-for-adults-with-multiple-sclerosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#4
Alexander Rae-Grant, Gregory S Day, Ruth Ann Marrie, Alejandro Rabinstein, Bruce A C Cree, Gary S Gronseth, Michael Haboubi, June Halper, Jonathan P Hosey, David E Jones, Robert Lisak, Daniel Pelletier, Sonja Potrebic, Cynthia Sitcov, Rick Sommers, Julie Stachowiak, Thomas S D Getchius, Shannon A Merillat, Tamara Pringsheim
OBJECTIVE: To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS). METHODS: A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine-compliant process to ensure transparency and patient engagement; and developed modified Delphi consensus-based recommendations concerning starting, switching, and stopping DMTs pertinent to people with relapsing-remitting MS, secondary progressive MS, primary progressive MS, and clinically isolated syndromes of demyelination...
April 24, 2018: Neurology
https://www.readbyqxmd.com/read/29685115/acquired-modification-of-sphingosine-1-phosphate-lyase-activity-is-not-related-to-adrenal-insufficiency
#5
Gulin Sunter, Ece Oge Enver, Azad Akbarzade, Serap Turan, Pinar Vatansever, Dilek Ince Gunal, Goncagul Haklar, Abdullah Bereket, Kadriye Agan, Tulay Guran
BACKGROUND: Congenital sphingosine-1-phosphate (S1P) lyase deficiency due to biallelic mutations in SGPL1 gene has recently been described in association with primary adrenal insufficiency and steroid-resistant nephrotic syndrome. S1P lyase, on the other hand, is therapeutically inhibited by fingolimod which is an oral drug for relapsing multiple sclerosis (MS). Effects of this treatment on adrenal function has not yet been evaluated. We aimed to test adrenal function of MS patients receiving long-term fingolimod treatment...
April 23, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29685071/comparative-analysis-of-natalizumab-versus-fingolimod-as-second-line-treatment-in-relapsing-remitting-multiple-sclerosis
#6
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Hänni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Özgür Yaldizli
BACKGROUND: No randomized controlled trials have compared the efficacy of fingolimod or natalizumab as second-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: To compare clinical outcomes after escalation to fingolimod versus natalizumab in patients with clinically active RRMS. METHODS: Using the registry of the Swiss Federation for Common Tasks of Health Insurances, we identified patients with RRMS and ≥1 relapse in the year before switching from interferon beta or glatiramer acetate to fingolimod or natalizumab...
April 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29673751/-primary-cutaneous-cd30-t-cell-lymphoproliferation-during-treatment-with-fingolimod-case-report-and-literature-review
#7
E Cesbron, J-B Monfort, C Giannesini, P Duriez, P Moguelet, P Senet, C Francès, A Barbaud, F Chasset
BACKGROUND: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. PATIENTS AND METHODS: A 56-year-old woman developed cutaneous indurated and ulcerated nodular lesions 6 months after starting fingolimod for active relapsing-remitting multiple sclerosis...
April 16, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29670818/fingolimod-promotes-blood-nerve-barrier-properties-in-vitro
#8
Hideaki Nishihara, Toshihiko Maeda, Yasuteru Sano, Maho Ueno, Nana Okamoto, Yukio Takeshita, Fumitaka Shimizu, Michiaki Koga, Takashi Kanda
Objective: The main effect of fingolimod is thought to be functional antagonism of lymphocytic S1P1 receptors and the prevention of lymphocyte egress from lymphoid tissues, thereby reducing lymphocyte infiltration into the nervous system. However, a growing number of reports suggest that fingolimod also has a direct effect on several cell types in the nervous system. Although we previously reported that fingolimod enhances blood-brain barrier (BBB) functions, there have been no investigations regarding the blood-nerve barrier (BNB)...
April 2018: Brain and Behavior
https://www.readbyqxmd.com/read/29669908/progressive-multifocal-leukoencephalopathy-after-fingolimod-treatment
#9
Joseph R Berger, Bruce A Cree, Benjamin Greenberg, Bernhard Hemmer, Brian J Ward, Victor M Dong, Martin Merschhemke
OBJECTIVE: We describe the characteristics of the 15 patients with fingolimod-associated progressive multifocal leukoencephalopathy (PML) identified from the Novartis data safety base and provide risk estimates for the disorder. METHODS: The Novartis safety database was searched for PML cases with a data lock point of August 31, 2017. PML classification was based on previously published criteria. The risk and incidence were estimated using the 15 patients with confirmed PML and the overall population of patients treated with fingolimod...
April 18, 2018: Neurology
https://www.readbyqxmd.com/read/29667130/beneficial-effects-of-the-calcium-channel-blocker-ctk-01512-2-in-a-mouse-model-of-multiple-sclerosis
#10
Rodrigo B M Silva, Samuel Greggio, Gianina T Venturin, Jaderson C da Costa, Marcus V Gomez, Maria M Campos
Voltage-gated calcium channels (VGCCs) play a critical role in neuroinflammatory diseases, such as multiple sclerosis (MS). CTK 01512-2 is a recombinant version of the peptide Phα1β derived from the spider Phoneutria nigriventer, which inhibits N-type VGCC/TRPA1-mediated calcium influx. We investigated the effects of this molecule in the mouse model of experimental autoimmune encephalomyelitis (EAE). The effects of CTK 01512-2 were compared to those displayed by ziconotide-a selective N-type VGCC blocker clinically used for chronic pain-and fingolimod-a drug employed for MS treatment...
April 17, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29666841/erratum-dramatic-rebounds-of-ms-during-pregnancy-following-fingolimod-withdrawal
#11
(no author information available yet)
[This corrects the article on p. e377 in vol. 4, PMID: 28804745.].
May 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29664454/clinical-effectiveness-and-safety-of-fingolimod-in-relapsing-remitting-multiple-sclerosis-in-western-iran
#12
Elham Ouspid, Nazanin Razazian, Abdorreza N Moghadasi, Nasrin Moradian, Daryoush Afshari, Arash Bostani, Payam Sariaslani, Atefeh Ansarian
OBJECTIVE: To investigate the clinical effectiveness and safety of fingolimod in the western Iranian population. METHODS: This study was performed as a prospective observational study between March 2014 and October 2015. Sixty patients with relapsing remitting multiple sclerosis (RRMS) who were referred to the MS clinic of Imam Reza Hospital, which is affiliated with Kermanshah University of Medical Sciences, Iran, were treated with 0.5 mg oral fingolimod capsules once daily for 12 months...
April 2018: Neurosciences: the Official Journal of the Pan Arab Union of Neurological Sciences
https://www.readbyqxmd.com/read/29663814/new-biological-agents-in-the-treatment-of-multiple-sclerosis
#13
M Buc
Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an introduction of biological agents to its treatment. Interferon beta and glatiramer acetate have been in clinical practice for more than 20 years. Nowadays, novel biologics, which target molecules involved in immunopathological processes more specifically have entered the scene. They are represented by monoclonal antibodies binding to molecules VLA4 (natalizumab), CD20 (ocrelizumab), CD52 (alemtuzumab) or alpha subunit of IL-2 receptor (daclizumab) or by small molecules such as those modulating the receptors involved in regulation of lymphocyte migration (fingolimod, ozanimod) or in induction of lymphopenia by apoptosis (dimethyl fumarate, cladribine)...
2018: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29656444/predicting-therapeutic-response-to-fingolimod-treatment-in-multiple-sclerosis-patients
#14
Bibiana Quirant-Sánchez, José V Hervás-García, Aina Teniente-Serra, Luis Brieva, Ester Moral-Torres, Antonio Cano, Elvira Munteis, María J Mansilla, Silvia Presas-Rodriguez, Juan Navarro-Barriuso, Cristina Ramo-Tello, Eva M Martínez-Cáceres
AIMS: Fingolimod, an orally active immunomodulatory drug for relapsing-remitting multiple sclerosis (RRMS), sequesters T cells in lymph nodes through functional antagonism of the sphingosine-1-phosphate receptor, reducing the number of potential autoreactive cells that migrate to the central nervous system. However, not all RRMS patients respond to this therapy. Our aim was to test the hypothesis that by immune-monitoring RRMS patient's leukocyte subpopulations it is possible to find biomarkers associated with clinical response to fingolimod...
April 15, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29648900/no-evidence-of-disease-activity-in-patients-receiving-fingolimod-at-private-or-academic-centers-in-clinical-practice-a-retrospective-analysis-of-the-multiple-sclerosis-clinical-and-magnetic-resonance-imaging-outcomes-in-the-usa-ms-mrius-study
#15
Robert Zivadinov, Nasreen Khan, Jonathan R Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Scott Kolodny, Diego Silva, Jennie Medin, Bianca Weinstock-Guttman
OBJECTIVE: The impact of multiple sclerosis (MS) center type on outcomes has not been investigated. This study aimed to evaluate baseline characteristics and clinical and magnetic resonance imaging (MRI) outcomes in patients with MS receiving fingolimod over 16 months' follow-up at private or academic centers in the USA. METHODS: Clinical and MRI data collected in clinical practice from patients initiating fingolimod were stratified by center type and retrospectively analyzed...
April 12, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29629942/paediatric-multiple-sclerosis-and-other-acute-demyelinating-diseases
#16
Kevin Rostásy, Barbara Bajer-Kornek
PURPOSE OF REVIEW: Neuroimmunological diseases encompass a wide spectrum of diseases in children. Apart from the discovery of autoantibodies affecting primarily grey matter structures and the improved clinical characterization of rare entities such as N-methyl D-aspartate receptor-R- encephalitis, important strides have also been made in autoimmune-mediated white matter diseases, including paediatric multiple sclerosis (pedMS) and other acute demyelinating syndromes (ADS) often associated with antibodies (abs) against myelin-oligodendrocyte-glycoprotein (MOG)...
April 7, 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29627016/real-world-persistence-with-fingolimod-for-the-treatment-of-multiple-sclerosis-a-systematic-review-and-meta-analysis
#17
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, James Signorovitch, Nanxin Li, Wei Gao, Valerie Koo, Emilie Duchesneau, Vivian Herrera
OBJECTIVE: To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate. METHODS: A systematic literature review was conducted (MEDLINE, EMBASE, and abstracts from selected conferences [2013-2015]) to identify observational studies reporting 1-year fingolimod persistence among adult patients with RRMS (sample size ≥50)...
May 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29623068/nuclear-insulin-like-growth-factor-binding-protein-3-as-a-biomarker-in-triple-negative-breast-cancer-xenograft-tumors-effect-of-targeted-therapy-and-comparison-with-chemotherapy
#18
Sohel M Julovi, Janet L Martin, Robert C Baxter
Triple-negative breast cancer (TNBC) typically has a worse outcome than other breast cancer subtypes, in part owing to a lack of approved therapeutic targets or prognostic markers. We have previously described an oncogenic pathway in basal-like TNBC cells, initiated by insulin-like growth factor binding protein-3 (IGFBP-3), in which the epidermal growth factor receptor (EGFR) is transactivated by sphingosine-1-phosphate (S1P) resulting from sphingosine kinase (SphK)-1 activation. Oncogenic IGFBP-3 signaling can be targeted by combination treatment with the S1P receptor modulator and SphK inhibitor, fingolimod, and the EGFR kinase inhibitor, gefitinib (F + G)...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29618748/fingolimod-therapy-is-not-effective-in-a-mouse-model-of-spontaneous-autoimmune-peripheral-polyneuropathy
#19
Petra Huehnchen, Wolfgang Boehmerle, Matthias Endres
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disorder, which causes progressive sensory and motor deficits and often results in severe disability. Knockout of the co-stimulatory protein CD86 in mice of the non-obese diabetic background (NoD.129S4-Cd86tm1Shr /JbsJ) results in the development of a spontaneous autoimmune peripheral polyneuropathy (SAPP). We used this previously described transgenic model to study the effects of the sphingosine-1-phosphate receptor agonist fingolimod on SAPP symptoms, functional and electrophysiological characteristics...
April 4, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29605798/health-care-cost-for-multiple-sclerosis-the-case-of-a-health-insurer-in-colombia
#20
Ivan Mauricio Muñoz-Galindo, Jairo Alexander Moreno Calderón, Natalia Elizabeth Guarín Téllez, Helbert Orlando Arévalo Roa, Jorge Augusto Díaz Rojas
BACKGROUND: There have been many studies on the cost of multiple sclerosis in countries with high prevalence, whereas in Latin America such analyses are few. Taking into consideration the burden of this disease and the high financial impact of treatment on the health care system, it is necessary to know the behavior of cost of illness. OBJECTIVES: To describe the direct costs associated with health care in patients with multiple sclerosis affiliated with a health insurer in Colombia...
March 29, 2018: Value in Health Regional Issues
keyword
keyword
27291
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"